FCGR2A and cancer: Among the 12 selected DEGs, the relative expression of RSL24D1 was down‐regulated in cancer patients' platelets, while IFI27, CRYM, HBD, IFITM3, FCGR2A, and KLHDC8B were up‐regulated in cancer patients' platelets, which was consistent with the results analyzed by using bioinformatics (Figure 7).